Systemic Lupus Erythematosus (SLE) is a heterogeneous multisystem autoimmune disease, with variable severity, autoantibody profile, response to treatment, relapsing course and damage accrual. The age at disease onset may influence disease trajectory and prognosis, with remarkable differences of major organ involvement, disease activity, and prognosis. SLE clinical profile, activity indices, remission, and damage comparison were carried out in childhood-onset (cSLE), adult-onset (aSLE) and late-onset (lSLE) patients from a single-centre series.
Methods
A cross-sectional analysis reviewing the clinical profile of SLE cases seen between 2012 and 2022 and classified in 3 age-groups according to disease onset: cSLE (<18 years), aSLE (18 to 49 years) and lSLE (>=50 years), was performed. Disease activity status was assessed by PGA (0-3), SLEDAI-2K, SLE-DAS, LLDAS and DORIS criteria, and damage using SDI at the same visit were compared in those 3 age-groups.
Results
Four hundred and fifteen patients were included in the analysis: 289 (68%) aSLE, 79 (19%) cSLE, and 47 (11.3%) lSLE. Most common clinical manifestations were articular (75.2%), hematological (70.1%), cutaneous (67.9%), photosensitivity (59.3%), and renal (41.7%). The clinical profile was similar among the subgroups of SLE patients, except for lSLE with lower frequency of nephritis and serositis, lower frequency of autoantibodies and hypocomplementenemia, lower SLEDAI-2K and SLE-DAS scores, and a higher frequency of LLDAS and DORIS remission; and a higher damage scores (SDI). Patients with cSLE had a significantly higher frequency of renal and neurological involvement, and a longer disease duration, but the disease activity, damage scores and remission rates were comparable to adult-onset group.
Conclusion
The remarkable differences among the 3-age-groups were higher frequency of renal and neuropsychiatric domains in youngsters and disease activity scores compared to other age-groups. The lSLE group had less nephritis and serositis, lower disease activity and higher damage scores.
Rivas-LarrauriFYamazaki-NakashimadaMA. Systemic lupus erythematosus: is it one disease?Reumatol Clin2016; 12(5): 274–281.
4.
GergianakiIBortoluzziABertsiasG. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol2018; 32(2): 188–205.
5.
FatoyeFGebryeTMbadaC. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. Rheumatol Int2022; 42(12): 2097–2107.
6.
FanouriakisATziolosNBertsiasG, et al.Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis2021; 80(1): 14–25.
7.
DörnerTFurieR. Novel paradigms in systemic lupus erythematosus. Lancet2019; 393(10188): 2344–2358.
8.
Van VollenhovenRFMoscaMBertsiasG, et al.Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis2014; 73(6): 958–967.
9.
FlorisAPigaMPerraD, et al.Treatment target in newly diagnosed systemic lupus erythematosus: the association of lupus low disease activity state and remission with lower accrual of early damage. Arthritis Care Res2020; 72(12): 1794–1799.
10.
Van VollenhovenRVoskuylABertsiasG, et al.A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis2017; 76(3): 554–561.
11.
FranklynKLauCSNavarraSV, et al.Definition and initial validation of a Lupus low disease activity state (LLDAS). Ann Rheum Dis2016; 75(9): 1615–1621.
12.
PigaMTseliosKViveirosL, et al.Clinical patterns of disease: from early systemic lupus erythematosus to late-onset disease. Best Pract Res Clin Rheumatol2023; 37(4): 101938.
13.
FengXZouYPanW, et al.Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus. Lupus2014; 23(3): 327–334.
14.
ChahadeWSatoEMouraJ, et al.Occasional series: lupus around the world systemic lupus erythematosus in São Paulo/Brazil: a clinical and laboratory overview. Lupus1995; 4(2): 100–103.
15.
BorbaEAraujoDBonfáE, et al.Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus2013; 22(7): 744–799.
16.
SassiRHHendlerJVPiccoliGF, et al.Age of onset influences on clinical and laboratory profile of patients with systemic lupus erythematosus. Clin Rheumatol2017; 36(1): 89–95.
17.
Das Chagas MedeirosMMBezerraMCBragaFNHF, et al.Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemic lupus erythematosus (SLE): comparison between childhood-onset, adult-onset, and late-onset SLE. Lupus2016; 25(4): 355–363.
18.
PetriM. Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am2005; 31(2): 245–254.
19.
PetriMOrbaiAAlarcónGS, et al.Derivation and validation of the systemic Lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64(8): 2677–2686.
20.
AringerMCostenbaderKDaikhD, et al.2019 European league against Rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis2019; 78(9): 1151–1159.
21.
WeeningJJD’agatiVDSchwartzMM, et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int2004; 65(2): 521–530.
22.
ChessaEPigaMFlorisA, et al.Use of physician global assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. Rheumatology2020; 59(12): 3622–3632.
JesusDMatosAHenriquesC, et al.Derivation and validation of the SLE disease activity score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis2019; 78(3): 365–371.
25.
Van VollenhovenRVoskuylABertsiasG, et al.A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis2017; 76(3): 554–561.
26.
SuttonEJDavidsonJEBruceIN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum2013; 43(3): 352–361.
27.
ThanouAJupeEPurushothamanM, et al.Clinical disease activity and flare in SLE: current concepts and novel biomarkers. J Autoimmun2021; 119: 102615.
28.
SohnIWJooYBWonS, et al.Late-onset systemic lupus erythematosus: is it “mild lupus”. Lupus2018; 27(2): 235–242.
29.
AlonsoMMartinez-VazquezFDe TeranTD, et al.Late-onset systemic lupus erythematosus in Northwestern Spain: differences with early-onset systemic lupus erythematosus and literature review. Lupus2012; 21(10): 1135–1148.
30.
MedhatBMBehiryMESobhyN, et al.Late-onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile- and adult-onset patients—a multicenter retrospective cohort. Clin Rheumatol2020; 39(2): 435–442.
31.
BrunnerHIGladmanDDIbañezD, et al.Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum2008; 58(2): 556–562.
32.
RovenskýJTuchyňováA. Systemic lupus erythematosus in the elderly. Autoimmun Rev2008; 7(3): 235–239.
33.
PadovanMGovoniMCastellinoG, et al.Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. Rheumatol Int2007; 27(8): 735–741.
34.
SousaSGonçalvesMJInêsLS, et al.Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register. Rheumatol Int2016; 36(7): 955–960.
35.
Tomic-LucicAPetrovicRRadak-PerovicM, et al.Late-onset systemic lupus erythematosus: clinical features, course, and prognosis. Clin Rheumatol2013; 32(7): 1053–1058.
36.
CharrasASmithEHedrichCM. Systemic Lupus erythematosus in children and young people. Curr Rheumatol Rep2021; 23(3): 20.
37.
AmbroseNMorganTAGallowayJ, et al.Differences in disease phenotype and severity in SLE across age groups. Lupus2016; 25(14): 1542–1550.
38.
Ramírez GómezLUribe UribeOOsio UribeO, et al.Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus2008; 17(6): 596–604.
39.
HoffmanIEALauwerysBRDe KeyserF, et al.Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis2009; 68(3): 412–415.
40.
LivingstonBBonnerAPopeJ. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus2011; 20(13): 1345–1355.
41.
HarryOYasinSBrunnerH. Childhood-onset systemic lupus erythematosus: a review and update. J Pediatr2018; 196: 22–30.e2.
42.
SmithEMDLythgoeHMidgleyA, et al.Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol2019; 209: 108274.
43.
AlexanderTHedrichCM. Systemic lupus erythematosus – are children miniature adults?Clin Immunol2022; 234: 108907.
44.
SilvaCAAvcinTBrunnerHI. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res2012; 64(12): 1787–1793.
45.
SmithEMDAggarwalAAinsworthJ, et al.PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS). Clin Immunol2023; 250: 109296.
46.
SmithEMDAggarwalAAinsworthJ, et al.Defining remission in childhood-onset lupus: pres-endorsed consensus definitions by an international task force. Clin Immunol2024; 263: 110214.
47.
NakashimaCAKGalhardoAPFiorenzanoGRet al.Incidence and clinical-laboratory aspects of systemic lupus erythematosus in a Southern Brazilian city. Rev Bras Reumatol. 2011 May-Jun;51(3):231–9. English, Portuguese PMID: 21625811.
48.
KlumbEMScheinbergMSouzaVAD, et al.The landscape of systemic lupus erythematosus in Brazil: an expert panel review and recommendations. Lupus2021; 30(10): 1684–1695.
49.
De AbreuMMMonticieloOAFernandesV, et al.Characterization of the patterns of care, access, and direct cost of systemic lupus erythematosus in Brazil: findings from the Macunaíma study. Adv Rheumatol2024; 64(1): 30.
50.
JohnsonSRGladmanDDBrunnerHI, et al.Evaluating the construct of damage in systemic lupus erythematosus. Arthritis Care Res2023; 75(5): 998–1006.
